This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Oxytetracycline and hydrocortisone topical


Ointment containing oxytetracycline and hydrocortisone.

Drugs List

  • oxytetracycline 3% and hydrocortisone 1% ointment
  • TERRA-CORTRIL ointment
  • Therapeutic Indications


    Skin infection - minor



    Apply to infected area 2 to 4 times a day.
    Some sources suggest a thin layer applied only once or twice a day may be sufficient.


    Children under 12 years

    Precautions and Warnings

    Exclude primary bacterial infection before treatment
    Avoid contact with eyes
    Occlusive dressings can increase the likelihood of systemic absorption
    Prolonged use over a large area may cause systemic absorption
    Monitor for signs of superinfection with non-susceptible organisms
    Extended or recurrent use may increase the risk of contact sensitisation
    Discontinue if local irritation occurs
    Discontinue if no improvement occurs within 7 days
    Discontinue if overgrowth of resistant organisms occurs
    Advise patient residue on clothing/bedding may cause fire hazard
    Fire hazard: Keep away from naked flames and potential sources of ignition

    Pregnancy and Lactation


    Use is contraindicated in pregnancy.

    Manufacturers advises there is a risk of damage to the permanent dentition if used during pregnancy.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use is contraindicated in Breastfeeding.

    Manufacturers advises there is a risk of damage to the permanent dentition if used during breastfeeding.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Acne-like eruptions
    Allergic contact dermatitis
    Allergic reaction
    Burning sensation
    Contact dermatitis
    Contact sensitisation
    Dry skin
    Irritation (localised)
    Maceration of skin
    Perioral dermatitis
    Secondary infections
    Skin atrophy


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2015

    Reference Sources

    Summary of Product Characteristics: Terra-cortril ointment. Alliance Pharmaceuticals Ltd. Revised December 2014.

    NICE Evidence Services Available at: Last accessed: 06 Septebember 2017

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.